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proach. Targeting protein kinase Cß (PKCß) may serve as an attractive 
candidate because activation of PKCß has been implicated in tumor 
proliferation, survival, invasion, and angiogenesis in model systems. 
Enzastaurin is a selective PKCß inhibitor. There is evidence for its ef-
ﬁcacy in both preclinical and clinical trials. The objective of this study 
was to assess the effect of enzastaurin on proliferation and phosphopro-
tein signaling in lung cancer. 
Methods: Four non small cell lung cancer (non-SCLC) cell lines 
(H125, H322, H23, A549) and four SCLC cell lines (H69, SW210.5, 
DMS-79, H211)] were tested. Cells were exposed to different doses of 
enzastaurin for 4 days, and the anti-proliferation effect was assessed 
with the CellTiter-Glo Luminescent Cell Viability Assay. The efﬁciency 
of enzastaurin in suppressing intracellular phosphoprotein signaling 
in these cells was tested at 1µmol/L concentrations at difference time 
points (0.5, 1, 2, 4 hours). PKCβII and phospho-PKCβII(ser660), 
GSK3β and phospho-GSK3β(ser9), ribosomal protein S6 and phospho- 
ribosomal protein S6(ser240/244) were measured by western blotting. 
Results: Enzastaurin suppressed cell proliferation of all NSCLC 
and SCLC cell lines in the low micromolar range (0.1, 1, 5µM). 
Western blot analysis of these cells showed that phosphorylation of 
PKCβII(ser660), GSK3β(ser9) and ribosomal protein S6(ser240/244) 
were suppressed in a time-dependent manner after enzastaurin treat-
ment.
Conclusions: These data indicate that enzastaurin has a direct anti-
cancer effect through suppression of proliferation, and they suggest 
that this effect is mediated by inhibition of intracellular phosphoprotein 
signaling.
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Background: RAD001C (everolimus) is an oral inhibitor of mamma-
lian target of rapamycin (mTOR) with anti-tumor activity. As single-
agent and in combination with other anticancer agents, RAD001C 
showed efﬁcacy in in vitro and in vivo NSCLC models. RAD001C is 
currently being investigated in clinical trials as an anticancer agent in 
patients with advanced lung cancer. In a phase I study, 4 disease stabili-
zations (SD) and 1 partial response (PR), as per RECIST, were reported 
from 14 NSCLC patients treated with RAD001C monotherapy. Further 
phase Ib studies have been designed to investigate the feasibility of dif-
ferent regimens combining RAD001 doses and schedules with selected 
standard chemotherapeutic agents in patients with advanced non-small 
cell lung cancer (NSCLC) and small cell lung cancer (SCLC). A novel 
statistical design was tailored to optimize the regimen selection in this 
combination phase Ib setting.
Methods: Three phase I, open-label, multi-center studies of RAD001 
with standard chemotherapy in patients with advanced NSCLC or 
SCLC are designed as an adaptive Bayesian dose-escalation scheme. 
This is based on a Time-to-DLT (Dose Limiting Toxicity) model esti-
mating the risk that patients experience a DLT within their ﬁrst cycle 
of treatment (as primary endpoint) or at any other time-point during the 
study. This novel statistical design improves on the traditional phase 
I designs. The adaptive nature of the Bayesian methodology allows 
the DLT rate to be re-evaluated at any time during the study, allowing 
quicker intervention following toxicity events, without the constraint of 
ﬁxed-size cohorts of patients. Decision-making takes into account all 
available information from all patients in the study thanks to the time-
to-event model. All toxicities occurring at any time during treatment 
are incorporated. In this phase Ib combination setting, the knowledge 
already available on the safety proﬁle of the individual agents allows to 
make full use of the Bayesian methodology to identify the optimal dose 
(in terms of toxicity proﬁle) for future studies. DLT rates are provided 
with model-based conﬁdence intervals. The way the design operates 
has been investigated under a variety of toxicity scenarios. In particu-
lar, the risk to choose too high (too toxic) or too low a dose has been 
calculated and discussed versus traditional designs.
Results: Studies are ongoing. Results will be provided as available 
with a discussion of advantages and disadvantages of the novel phase I 
study design.
Conclusions: This adaptive phase Ib study design may be considered 
as a better decision-making tool which can exploit all safety informa-
tion available and ensure higher conﬁdence in the regimen selected for 
later phase clinical studies.
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Purpose: To fully explore the clinical possibility of honokiol, we 
encapsulated honokiol with long circulating liposome to improve its 
solubility and prolong its circulation time in body. The potential to in-
crease the antitumor effect of liposomal honokiol by combination with 
cisplatin and possible mechanism have been investigated in in vitro and 
in vivo. 
Experimental Design: Honokiol was encapsulated with long circulat-
ing modiﬁed liposomes. The pharmacokinetic study and biodistribution 
of liposomal honokiol in tumor-bearing mice was detected by high 
performance liquid chromatography. Inhibition of cell proliferation and 
induction of apoptosis by liposomal honokiol were tested in vitro. In 
in vivo study, LL/2 tumor model and human A549 tumor models were 
established in C57BL/6N mice and athymic nude mice, respectively. 
Mice were treated with PBS group, liposomal honokiol, free lipo-
some, cisplatin, and liposomal honokiol plus cisplatin. Tumor volume 
and survival time were observed and the mechanisms underlying the 
anti-tumor effect was investigated by detecting the microvessel density, 
apoptosis in tumor tissue.
Results: Liposomal honokiol has shown remarkable improvement 
of water solubility and could be dissolved in PBS for i.p injection. 
